Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;23(2):147-148.
doi: 10.1016/S1473-3099(22)00831-3. Epub 2023 Jan 5.

Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage

Prerna Arora  1 , Anne Cossmann  2 , Sebastian R Schulz  3 , Gema Morillas Ramos  4 , Metodi V Stankov  2 , Hans-Martin Jäck  3 , Georg M N Behrens  5 , Stefan Pöhlmann  1 , Markus Hoffmann  6
Affiliations

Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage

Prerna Arora et al. Lancet Infect Dis. 2023 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

SP and MH do contract research on the testing of vaccinee serum samples for neutralising activity against SARS-CoV-2 for Valneva, unrelated to this work. GMNB served as an advisor for Moderna and SP served as an advisor for BioNTech, unrelated to this work. All other authors declare no competing interests. SP acknowledges funding for this project by the German Federal Ministry of Education and Research (01KI2006D), the EU project UNDINE (grant agreement number 101057100), the Ministry for Science and Culture of Lower Saxony (14-76103-184, MWK HZI COVID-19), and the German Research Foundation (PO 716/11-1 and PO 716/14-1). H-MJ received funding from the German Federal Ministry of Education and Research (01KI2043, NaFoUniMedCovid19-COVIM 01KX2021), Bavarian State Ministry for Science and the Arts; and DFG through the research training groups RTG1660 and TRR130, the Bayerische Forschungsstiftung (Project CORAd), and the Kastner Foundation. GMNB acknowledges funding by the German Center for Infection Research (grant number 80018019238) and a European Regional Development Fund (Defeat Corona, ZW7-8515131). The funding sources had no role in study design, data collection, data analysis, data interpretation, writing of the Correspondence, or the decision to submit the manuscript for publication. We did not receive payment by a pharmaceutical company or other agency to write this Correspondence. We were not precluded from accessing data in the study and we accept responsibility to submit for publication.

Figures

Figure
Figure
Sensitivity of the SARS-CoV-2 XBB.1 lineage to neutralisation by monoclonal antibodies, antibodies induced by vaccination, and antibodies induced by vaccination plus breakthrough infection (A) Sensitivity of the SARS-CoV-2 XBB.1 lineage to neutralisation by monoclonal antibodies. Pseudoviruses were preincubated with different concentrations of individual mAb or mAb cocktails before being inoculated onto Vero cells. At 16–18 h after inoculation, pseudovirus entry was analysed, normalised against samples without mAb (0% inhibition), and the EC50, which indicates the mAb concentration required for half-maximal inhibition, was calculated. Data represent the mean of three biological replicates (done with four technical replicates; appendix pp 3–6 and 11–12 for details on the experimental set-up and additional data). (B) Sensitivity of the SARS-CoV-2 XBB.1 lineage to neutralisation by antibodies induced by vaccination or vaccination plus breakthrough infection. Pseudoviruses were preincubated with serially diluted plasma and subsequently inoculated onto Vero cells. At 16–18 h after inoculation, pseudovirus entry was analysed and the NT50 was calculated. Data represent geometric mean NT50 values from a single biological replicate (done with four technical replicates). Numbers in brackets indicate NT50 values and percentages above the graphs represent responder rates (ie, proportion of samples with detectable neutralising activity). Dashed lines indicate the lowest plasma dilution tested. We used the Wilcoxon matched pairs signed rank test to analyse the statistical significance of the effects observed (appendix pp 13–16 for individual data). BTI=breakthrough infection. EC50=effective concentration 50. mAb=monoclonal antibodies. NT50=neutralising titre 50.
See this image and copyright information in PMC

References

    1. Focosi D, Maggi F. Recombination in coronaviruses, with a focus on SARS-CoV-2. Viruses. 2022;14 - PMC - PubMed
    1. Taghizadeh P, Salehi S, Heshmati A, et al. Study on SARS-CoV-2 strains in Iran reveals potential contribution of co-infection with and recombination between different strains to the emergence of new strains. Virology. 2021;562:63–73. - PMC - PubMed
    1. Turakhia Y, Thornlow B, Hinrichs A, et al. Pandemic-scale phylogenomics reveals the SARS-CoV-2 recombination landscape. Nature. 2022;609:994–997. - PMC - PubMed
    1. Wertheim JO, Wang JC, Leelawong M, et al. Detection of SARS-CoV-2 intra-host recombination during superinfection with alpha and epsilon variants in New York city. Nat Commun. 2022;13 - PMC - PubMed
    1. Chen C, Nadeau S, Yared M, et al. CoV-spectrum: analysis of globally shared SARS-CoV-2 data to identify and characterize new variants. Bioinformatics. 2021;38:1735–1737. - PMC - PubMed

Publication types

Substances